Search

Displaying results 4321 - 4330 of 6076 in total
  1. Drug

    Hemoximer

    go.drugbank.com/drugs/DB17600
    Investigational

    Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.

  2. Drug

    CDX-6512

    go.drugbank.com/drugs/DB17841
    Experimental

    Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]

  3. Drug

    Deuremidevir

    go.drugbank.com/drugs/DB26606
    Investigational

    Deuremidevir is under investigation in clinical trial NCT06328400 (A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension).

  4. Drug

    Etofibrate

    go.drugbank.com/drugs/DB08983
    Experimental

    These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.

  5. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    It is developed for the treatment of solid tumors.

  6. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  7. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  8. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

  9. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  10. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    Additional preliminary findings support its use for the management of some B-cell malignancies.